Todd M. Bauer

17.1k citations
264 papers · 8.8k · 6 hit papers · h-index 50

Impact in

  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • HER2/EGFR in Cancer Research
    • CAR-T cell therapy research
    • Lung Cancer Treatments and Mutations

Papers in

    • Cancer Immunotherapy and Biomarkers 46
    • Lung Cancer Research Studies 25
    • Colorectal Cancer Treatments and Studies 24
    • CAR-T cell therapy research 23
    • Lung Cancer Treatments and Mutations 71
    • Renal cell carcinoma treatment 23

Todd M. Bauer

255 papers receiving 8.7k citations

Todd M. Bauer's Hit Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study 2024 · 132 citations
1320+3+6Years since publication200400600

Peers

Todd M. Bauer
Comparison fields: 5 of 113
  • Oncology 4.5k
  • Pulmonary and Respiratory Medicine 3.8k
  • Biological Psychiatry 202
  • Cancer Research 1.2k
  • Immunology 1.3k
Replace Ana Arance with:
Ana Arance Spain
Shumei Kato United States
Johanna C. Bendell United States
Reshma Rangwala United States
Alberto Chiappori United States
Anthony M. Joshua Australia
Jamie E. Chaft United States
Bart Neyns Belgium
Marcin Kowanetz United States
Bartosz Chmielowski United States
Todd M. Bauer relative to Ana Arance Spain Ana Arance's profile →
Citations per field
00.5×3.2×
Ana Arance · 1×
Citations per year

Countries citing papers authored by Todd M. Bauer

Since Specialization
Citations

This map shows the geographic impact of Todd M. Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd M. Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd M. Bauer more than expected).

Fields of papers citing papers by Todd M. Bauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd M. Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd M. Bauer. The network helps show where Todd M. Bauer may publish in the future.

Co-authors

The 25 scholars most cited alongside Todd M. Bauer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Todd M. Bauer Line = papers co-authored together Todd M. Bauer links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 264 papers — load more, or switch the sort, to bring in the rest.

#Work
1
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Hit paper breakdown →
2020676
2
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Hit paper breakdown →
2017490
3 2018315
4 2019274
5
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
Hit paper breakdown →
2019254
6
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Hit paper breakdown →
2021207
7 2017181
8 2015176
9 2017174
10 2016174
11 2016149
12 2018148
13
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Hit paper breakdown →
2022136
14
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Hit paper breakdown →
2024132
15 2014122
16 2016120
17 2021117
18 2019117
19 2019116
20 2017113

About Todd M. Bauer

Todd M. Bauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Immunology, having authored 264 papers that have together received 8.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (71 papers), Cancer Immunotherapy and Biomarkers (46 papers), Cancer Genomics and Diagnostics (29 papers), Lung Cancer Research Studies (25 papers), Colorectal Cancer Treatments and Studies (24 papers), Renal cell carcinoma treatment (23 papers), CAR-T cell therapy research (23 papers) and Cancer Research and Treatments (21 papers). The work is most often cited by research in Oncology (4.5k citations), Pulmonary and Respiratory Medicine (3.8k citations), Biological Psychiatry (202 citations), Cancer Research (1.2k citations) and Immunology (1.3k citations). Todd M. Bauer has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Alice T. Shaw, Benjamin Solomon, Enriqueta Felip, Holger Thurm, Manish R. Patel, Gerson Peltz, Benjamin Besse, Antonello Abbattista, Jeffrey R. Infante and Jill S. Clancy. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Journal of Thoracic Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact